• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Corrigendum to "Bispecific antibodies" [Drug Discov. Today 20 (July (7)) (2015) 838-847].

作者信息

Kontermann Roland E, Brinkmann Ulrich

机构信息

Institute of Cell Biology and Immunology, University of Stuttgart, Stuttgart, Germany.

Roche Pharma Research and Early Development (pRED), Large Molecule Research, Roche Innovation Center Penzberg, Penzberg, Germany.

出版信息

Drug Discov Today. 2019 Jul;24(7):1422. doi: 10.1016/j.drudis.2017.12.004. Epub 2018 Jan 5.

DOI:10.1016/j.drudis.2017.12.004
PMID:29309739
Abstract
摘要

相似文献

1
Corrigendum to "Bispecific antibodies" [Drug Discov. Today 20 (July (7)) (2015) 838-847].《双特异性抗体》的勘误[《今日药物发现》20（2015年7月（7））838 - 847]
Drug Discov Today. 2019 Jul;24(7):1422. doi: 10.1016/j.drudis.2017.12.004. Epub 2018 Jan 5.
2
Corrigendum to "d-Arginine as a neuroprotective amino acid: promising outcomes for neurological diseases" [Drug Discov. Today 19 (2014) 627-636].《“D-精氨酸作为一种神经保护氨基酸：神经系统疾病的良好前景”的勘误》[《药物研发动态》19 (2014) 627 - 636]
Drug Discov Today. 2014 Nov;19(11):1829. doi: 10.1016/j.drudis.2014.08.002. Epub 2014 Aug 22.
3
Corrigendum to "Amyloid beta modulators and neuroprotection in Alzheimer's disease: a critical appraisal" [Drug Discov. Today 22 (February (2)) (2017) 223-233].《阿尔茨海默病中的淀粉样β调节剂与神经保护：批判性评估》的勘误[《今日药物发现》22（2017年2月（2））223 - 233]
Drug Discov Today. 2019 Jul;24(7):1423. doi: 10.1016/j.drudis.2017.12.003. Epub 2018 Jan 5.
4
Corrigendum to "Tocotrienols: the unsaturated sidekick shifting new paradigms in vitamin E therapeutics" [Drug Discov. Today 22 (December (12)) (2017) 1765-1781].《生育三烯酚：在维生素E治疗中转变新范式的不饱和伙伴》的勘误[《今日药物发现》22（12月（12））（2017年）1765 - 1781]
Drug Discov Today. 2019 Jul;24(7):1421. doi: 10.1016/j.drudis.2018.02.010. Epub 2018 Mar 7.
5
Corrigendum to "Reactivating mutant p53 using small molecules as zinc metallochaperones: awakening a sleeping giant in cancer" [Drug Discov. Today 20 (11) (2015) 1391-1397].《“利用小分子作为锌金属伴侣激活突变型p53：唤醒癌症中的沉睡巨头”的勘误》[《药物研发动态》20 (11) (2015) 1391 - 1397]
Drug Discov Today. 2016 Oct;21(10):1728. doi: 10.1016/j.drudis.2016.07.012. Epub 2016 Jul 29.
6
Corrigendum to "Metabolomics and systems pharmacology: why and how to model the human metabolic network for drug discovery" [Drug Discov. Today 19 (2014), 171-182.《代谢组学与系统药理学：为何以及如何构建用于药物发现的人类代谢网络模型》的勘误 [《今日药物发现》19 (2014), 171 - 182]
Drug Discov Today. 2014 Nov;19(11):1828. doi: 10.1016/j.drudis.2014.03.019. Epub 2014 Mar 31.
7
Corrigendum to 'Synthetic lethality: a step forward for personalized medicine in cancer' [Drug Discov. Today 25 (2020) 305-320].《“合成致死性：癌症个性化医疗的一大进步”的勘误》[《药物研发动态》25 (2020) 305 - 320]
Drug Discov Today. 2021 Aug;26(8):2077. doi: 10.1016/j.drudis.2020.07.016. Epub 2020 Jul 23.
8
Corrigendum to "The European Lead Factory: An updated HTS compound library for innovative drug discovery" [Drug Discov. Today 26(10) (2021) 2406-2413].《欧洲先导化合物工厂：用于创新药物发现的更新的高通量筛选化合物库》[《药物发现今日》26(10) (2021) 2406 - 2413]的勘误
Drug Discov Today. 2023 Aug;28(8):103257. doi: 10.1016/j.drudis.2022.04.005. Epub 2022 Apr 7.
9
Corrigendum to "Pharmacological modulation of autophagy for epilepsy therapy: Opportunities and obstacles" [Drug Discov. Today 28(6) (2023) 103600].《癫痫治疗中自噬的药理学调控：机遇与障碍》的勘误[《今日药物发现》28(6)(2023)103600]
Drug Discov Today. 2023 Aug;28(8):103651. doi: 10.1016/j.drudis.2023.103651. Epub 2023 Jun 5.
10
Corrigendum to "NCp7: targeting a multitask protein for next-generation anti-HIV drug development part 2. Noncovalent inhibitors and nucleic acid binders" [Drug Discov. Today 23(2018) 687-695].《“NCp7：靶向多功能蛋白用于下一代抗HIV药物研发 第2部分。非共价抑制剂和核酸结合剂”的勘误》[《今日药物发现》23(2018) 687 - 695]
Drug Discov Today. 2021 Aug;26(8):2075. doi: 10.1016/j.drudis.2019.12.002. Epub 2019 Dec 17.

引用本文的文献

1
Safety landscape of bispecific antibody therapy in non-Hodgkin lymphoma: a meta-analysis.双特异性抗体疗法在非霍奇金淋巴瘤中的安全性概况：一项荟萃分析
Blood Neoplasia. 2024 Dec 4;2(1):100061. doi: 10.1016/j.bneo.2024.100061. eCollection 2025 Feb.
2
Comparative Analysis of Bispecific Antibodies and CAR T-Cell Therapy in Follicular Lymphoma.滤泡性淋巴瘤中双特异性抗体与嵌合抗原受体T细胞疗法的比较分析
Eur J Haematol. 2025 Jan;114(1):4-16. doi: 10.1111/ejh.14335. Epub 2024 Oct 27.
3
Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities.
双特异性抗体治疗 B 细胞淋巴瘤：前景、未知与机遇
Blood. 2023 Feb 2;141(5):467-480. doi: 10.1182/blood.2021011994.
4
Development of a Bispecific Nanobody Targeting CD20 on B-Cell Lymphoma Cells and CD3 on T Cells.一种靶向B细胞淋巴瘤细胞上的CD20和T细胞上的CD3的双特异性纳米抗体的研发。
Vaccines (Basel). 2022 Aug 17;10(8):1335. doi: 10.3390/vaccines10081335.